Thelansis

Inflammatory Myositis (IM) Market Outlook Thelansis’s “Inflammatory Myositis (IM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inflammatory Myositis (IM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market...

  Inflammatory Myositis (IM) Market Outlook Thelansis’s “Inflammatory Myositis (IM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inflammatory Myositis (IM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Inflammatory Myositis (IM) Overview Inflammatory myopathies represent a spectrum of muscular disorders characterized by inflammation, stemming from autoimmune dysregulation wherein the body’s immune system erroneously targets its own muscle tissues. Predominant among these conditions are dermatomyositis and polymyositis, though the taxonomy of inflammatory myopathies remains dynamic, with ongoing identification of novel subt...

  Inflammatory myopathies represent a spectrum of muscular disorders characterized by inflammation, stemming from autoimmune dysregulation wherein the body's immune system erroneously targets its own muscle tissues. Predominant among these conditions are dermatomyositis and polymyositis, though the taxonomy of inflammatory myopathies remains dynamic, with ongoing identification of novel subtypes. Dermatomyositis primarily manifests as muscle weakness, notably affecting the musculature of the cervical, scapular, and pelvic regions, and also presents with cutaneous manifestations. Respiratory compromise may also ensue in some instances. While inflammatory myopathies can affect individuals across age groups and ethnicities, their incidence is relatively infrequent, with a predilection for onset in childhood (typically between ages 5 and 10) and adulthood (typically between ages 40 and 50) and a higher occurrence in females compared to males. The clinical evaluation of susp...